L
Lars Groth Grunnet
Researcher at University of Copenhagen
Publications - 10
Citations - 563
Lars Groth Grunnet is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Proinflammatory cytokine & Chemokine. The author has an hindex of 9, co-authored 10 publications receiving 514 citations. Previous affiliations of Lars Groth Grunnet include Steno Diabetes Center.
Papers
More filters
Journal ArticleDOI
Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus
Dan Ploug Christensen,Mattias S. Dahllöf,Morten Lundh,Daniel N Rasmussen,Mette D. Nielsen,Nils Billestrup,Lars Groth Grunnet,Thomas Mandrup-Poulsen +7 more
TL;DR: It is proposed that there is a strong rationale for preclinical studies and clinical trials with the aim of testing the utility of HDACi as a novel therapy for diabetes.
Journal ArticleDOI
High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression.
Rikard G. Fred,Claus Heiner Bang-Berthelsen,Thomas Mandrup-Poulsen,Thomas Mandrup-Poulsen,Lars Groth Grunnet,Nils Welsh +5 more
TL;DR: Prolonged high-glucose exposure down-regulates PTB levels and insulin biosynthesis rates in human islets by increasing miR-133a levels, and it is proposed that this mechanism contributes to hyperglycemia-induced beta-cell dysfunction.
Journal ArticleDOI
Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection.
Dan Ploug Christensen,Conny Gysemans,Morten Lundh,Mattias S. Dahllöf,Daniel Noesgaard,Søren Fisker Schmidt,Susanne Mandrup,Nicolai Juul Birkbak,Christopher T. Workman,Lorenzo Piemonti,Lykke Blaabjerg,Valmen Monzani,Gianluca Fossati,Paolo Mascagni,Steven Paraskevas,Reid Aikin,Nils Billestrup,Lars Groth Grunnet,Charles A. Dinarello,Chantal Mathieu,Thomas Mandrup-Poulsen +20 more
TL;DR: Lysine deacetylase inhibitors (KDACi) protect β-cells from inflammatory destruction in vitro and are promising immunomodulators and provide a rationale for clinical trials of safety and efficacy of KDACi in patients with autoimmune disease such as type 1 diabetes.
Journal ArticleDOI
Transporter function and cyclic AMP turnover in normal colonic mucosa from patients with and without colorectal neoplasia
Karen Kleberg,Gerda Majgaard Jensen,Dan Ploug Christensen,Morten Lundh,Lars Groth Grunnet,S. Knuhtsen,Steen Seier Poulsen,Mark Berner Hansen,Niels Bindslev +8 more
TL;DR: Colorectal neoplasia is associated with lower transport or sensitivity to cyclic nucleotides and increased expression of OATP2B1 and OatP4A1 transporters, known to transport PGE2.
Journal ArticleDOI
Altering β-cell number through stable alteration of miR-21 and miR-34a expression.
Marie Balslev Backe,Guy Wayne Novotny,Dan Ploug Christensen,Lars Groth Grunnet,Thomas Mandrup-Poulsen +4 more
TL;DR: The potential of miR-21 as a therapeutic agent to increase β-cell survival is doubtful, but as apoptosis and NO synthesis were highly reduced,miR-34a may be further investigated as a therapy target to reduce β- cell death and dysfunction.